Healome Therapeutics Secures £2M to Advance Eye Drop Technology
BIRMINGHAM, United Kingdom, July 7, 2026 Healome Therapeutics, a University of Birmingham spinout developing an innovative eye-drop matrix technology...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
BIRMINGHAM, United Kingdom, July 7, 2026 Healome Therapeutics, a University of Birmingham spinout developing an innovative eye-drop matrix technology...
NEW YORK, July 7, 2026 Regal Healthcare Capital Partners has successfully completed the final close of Fund IV, securing...
SHANGHAI, China, June 15, 2026 CARsgen Therapeutics Holdings Limited has unveiled encouraging clinical data for its investigational allogeneic CAR...
NEW YORK and ATHENS, Greece, June 13, 2026 Kos Biotechnology Partners has announced the successful third closing of its...
